@article{JTD25921,
author = {Tong Zhou and Xiaoyue Zhou and Peng Li and Chuang Qi and Yang Ling},
title = {EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {12},
year = {2018},
keywords = {},
abstract = {EGFR mutation is an important driving event in the development of non-small cell lung cancer (NSCLC), especially in pathologically diagnosed lung adenocarcinoma and non-smoking women in Asia (1). Compared with traditional platinum-containing chemotherapy, NSCLC patients with certain EGFR sensitive mutations showed higher clinical response to EGFR tyrosine kinase inhibitors (EGFR-TKIs), as confirmed by a series of phase III clinical trials, such as WJTOG3405, OPTIMAL, LUXLUNG6 and so on.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/25921}
}